A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer

Launched by ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL · Mar 18, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medication called Fasudil Hydrochloride to see if it can help treat a specific type of ovarian cancer that is linked to certain genetic traits. The researchers want to find out if the effects of this medication can also give insights into how well immunotherapy might work for other cancers, like non-small cell lung cancer. They plan to enroll 20 female patients aged 65 to 74 who have been treated with chemotherapy and have shown either stable disease or disease progression. To join the study, patients need to have a specific genetic marker (the A/A genotype) confirmed through testing.

Participants in this trial will receive Fasudil along with their original chemotherapy treatment. Before joining, patients should be in good health overall and not have serious conditions like low blood pressure, bleeding problems, or liver issues. If you're considering participating, you’ll need to provide informed consent, meaning you understand the study and agree to take part. This trial is actively recruiting patients, so it could be an opportunity to explore new treatment options for ovarian cancer.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients voluntarily participate in the study, sign informed consent forms, and have good compliance.
• • 2. After platinum based chemotherapy at Zhejiang Provincial People's Hospital, the efficacy evaluation showed that ovarian cancer patients who achieved disease stability (SD) or disease progression (PD) twice were treated with Fasudil in combination with the original chemotherapy regimen, and were confirmed to have the A/A genotype through genetic testing.
• Exclusion Criteria:
• • 1.Accompanied by hypotension 2. Bleeding like cerebral hemorrhage 3. Patients with abnormal liver function